Abstracts tagged "rheumatoid arthritis"

Abstract Number: 1778 • ACR Convergence 2022
More Than Half of RA Patients with a Lifetime History of Mood Disorders or Anxious and Depressed During COVID-19 Pandemic
Susan Bartlett¹, orit schieir², Marie-France Valois², Diane Tin³, Glen Hazlewood⁴, Louis Bessette⁵, Gilles Boire⁶, Carol Hitchon⁷, Janet Pope⁸, Carter Thorne⁹ and Vivian Bykerk¹⁰, ¹McGill University, Montreal, QC, Canada, ²McGill University, Montréal, QC, Canada, ³The Arthritis Program Research Group, Newmarket, ON, Canada, ⁴University of Calgary, Calgary, AB, Canada, ⁵Centre de l'Ostoporose et de Rhumatologie de Québec, Québec, QC, Canada, ⁶Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸University of Western Ontario, London, ON, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Hospital for Special Surgery, New York, NY
Background/Purpose: Chronic stress and chronic disease are risk factors for anxiety and depression. In Canadians with RA, pandemic-related stress was exacerbated by delayed access to…
Abstract Number: 1961 • ACR Convergence 2022
COVID-19 mRNA Vaccine Induced Antibody Titers and IFN-g Responses Are Decreased in Persons with Rheumatoid Arthritis and Older Age
Holly Dudley¹, megan O'Mara², Ann Auma¹, Jenny Gong³, Yael Ross⁴, Natalie Gurevich², Larraine Gordesky⁵, Nora Singer⁶, Lenche Kostadinova⁷, Brigid Wilson⁷, David Zidar⁷, Christopher King¹, David Canaday¹, Carey Shive¹, Maya Mattar⁸ and Donald Anthony⁹, ¹Case Western Reserve University, Cleveland, OH, ²Cleveland Veteran Affairs Medical Center, Cleveland, OH, ³Case Western School of Medicine, Cleveland, OH, ⁴Case Western Reserve University at MetroHealth Medical Center, Atlanta, GA, ⁵MetroHealth Medical Center, Cleveland, OH, ⁶The MetroHealth System at Case Western Reserve University School of Medicine, Cleveland, OH, ⁷VA Medical Center, Cleveland, OH, ⁸Louis Stokes VA Medical Center, Mayfield Heights, OH, ⁹Case, VA, Metro, Chardon, OH
Background/Purpose: People with autoimmune diseases have worse outcomes if infected by SARS-CoV2. In particular, persons with rheumatoid arthritis (RA), have lower antibody responses to COVID-19…
Abstract Number: 1979 • ACR Convergence 2022
Tc99m Tilmanocept Imaging Can Differentiate the Fibroid Pathotype of Rheumatoid Arthritis from Non-Fibroid Pathotypes in Patients
Costantino Pitzalis¹, rebecca hands², Swamy Venuturupalli³, Ami Ben-artzi⁴, Eric Ruderman⁵, Harris Perlman⁶, Arthur Mandelin⁵, Mara Leach⁷, Addison Hasselbach⁷, Bonnie Abbruzzese⁷, Rachael Hershey⁷, Beth Potter⁷, Jessica Fitzpatrick⁷, Aaron Thornton⁷, Michael Blue⁷, Jonathan Graf⁸, David Ralph⁷ and Michael Rosol⁷, ¹Queen Mary University of London, London, United Kingdom, ²William Harvey Research Institute, London, United Kingdom, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Ami Ben-Artzi, MD Inc., Beverly Hills, CA, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University, Chicago, IL, ⁷Navidea Biopharmaceuticals, Dublin, OH, ⁸Ucsf, San Francisco, CA
Background/Purpose: The primary objective of this study is to assess the relationship between joint-specific Tc99m tilmanocept (TIL) uptake values and the pathobiology of RA-involved joint…
Abstract Number: 1996 • ACR Convergence 2022
Individual Patient Data Meta-analysis on Continued Use of Glucocorticoids After Their Use as Bridging Therapy in Patients with Rheumatoid Arthritis
Lotte van Ouwerkerk¹, Patrick Verschueren², Pascal de Jong³, Paul Emery⁴, Josef Smolen⁵, Robert Landewé⁶, Willem Lems⁷, Maarten Boers⁸, Tom Huizinga¹, CF Allaart¹ and Sytske Anne Bergstra⁹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University Hospital Leuven, Leuven, Belgium, ³ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Medical University of Vienna, Vienna, Austria, ⁶Amsterdam University Medical Center, Meerssen, Netherlands, ⁷Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁸Amsterdam UMC, Vrije Universiteit, Amsterdam, Netherlands, ⁹LUMC, Leiden, Netherlands
Background/Purpose: Short-term (< 3 months) treatment with glucocorticoids (GC) ("bridging") is recommended in the EULAR 2019 rheumatoid arthritis (RA) recommendations when starting a csDMARD in…
Abstract Number: 2012 • ACR Convergence 2022
Predictors of Remission in Rheumatoid Arthritis Patients Treated with Biologics: A Systematic Review and Meta-analysis
Yasmin Khader, Azizullah Beran, Sami Ghazaleh, Rawish Fatima, Ashu Acharya and Nezam Altorok, University of Toledo, Toledo, OH
Background/Purpose: Biologic disease-modifying antirheumatic drugs (bDMARDs) have emerged as an effective treatment of rheumatoid arthritis (RA), improving patients’ quality of life throughout the disease course.…
Abstract Number: 2215 • ACR Convergence 2022
Reducing Cardiovascular Risk with Immunomodulators: A Single Blind Randomized Active Comparator Trial Among Patients with Rheumatoid Arthritis
Daniel Solomon¹, Jon Giles², Katherine Liao¹, Paul Ridker¹, Pamela Rist¹, Robert Glynn¹, Rachel Broderick³, Fengxin Lu¹, Meredith Murray¹, Kathleen Vanni¹, Leah Santacroce¹, Shady Abohashem⁴, Philip Robson⁵, Zahi Fayad⁶, Venkatesh Mani⁵, Ahmed Tawakol⁴ and Joan Bathon⁷, ¹Brigham and Women's Hospital, Boston, MA, ²Columbia University, New York, NY, ³Columbia University, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵Icahn School of Medicine at Mount Sinai, New York, NY, ⁶Mount Sinai, New York, NY, ⁷Columbia University Medical Center, New York, NY
Background/Purpose: Recent large-scale randomized trials demonstrate that immunomodulators reduce the risk of cardiovascular (CV) events among the general population with atherosclerosis. However, it is uncertain…
Abstract Number: PP12 • ACR Convergence 2022
We Became Advocates, Educators, and a Support System for Hispanic/Latino Patients with Rheumatoid Arthritis and Their Caregivers Through Involvement in a Virtual Patient Advisory Board
Zucy Almonacid¹, Wigna Cruz², Francisca Garcia³, Teresa Hernandez⁴, Velia Martinez⁵, Patricia Mattos³, Mario Mutis⁶ and Denise Serrano⁷, ¹Hicsville, NY, ²Juan Diaz, PR, ³Lake Worth, FL, ⁴Greenacres, FL, ⁵Guaynabo, PR, ⁶Fort Pierce, FL, ⁷Toa Alto, PR
Background/Purpose: Each of us has been diagnosed with rheumatoid arthritis (RA), from as recently as one year ago to as long as 20 years ago.…
Abstract Number: 0015 • ACR Convergence 2022
Differential Antigen Binding of Closely Related Monoclonal ACPA
Caroline Grönwall¹, Anatoly Dubnovitsky¹, Philip Titcombe², Daniel Mueller² and vivianne malmström¹, ¹Karolinska Institutet, Stockholm, Sweden, ²University of Minnesota, Minneapolis, MN
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are a hallmark of rheumatoid arthritis (RA) and the clonality and antigen targets of ACPA positive B cells can be…
Abstract Number: 0077 • ACR Convergence 2022
Rheumatoid Arthritis – Are We Getting to Target?
myint Thway¹, Gurjit S. Kaeley², Karishma Ramsubeik³, Laurie Ramrattan¹, Lilian Otalora Rojas⁴ and Sukhraj Singh¹, ¹University of Florida-Jacksonville, Jacksonville, FL, ²UF COM-J, Ponte Vedra Beach, FL, ³University of Florida, Jacksonville, FL, ⁴University of Florida, Ponte Vedra Beach, FL
Background/Purpose: Low disease activity (LDA) is a key goal in treating Rheumatoid arthritis, but implementing the treat to target approach in clinical practice has been…
Abstract Number: 0195 • ACR Convergence 2022
Acceptance of Virtual Reality for Managing Their Disease Among People with Rheumatologic Conditions with and Without Prior Experience Using Virtual Reality
Jeffrey Curtis¹, Kimberly Garza², Cassie Clinton³, Heqin Yang², Alexicia Richardson², Cheryl Seals², Gary Hawkins², Chad Rose², William Benjamin Nowell⁴, Kelly Gavigan⁵ and Liana Fraenkel⁶, ¹Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Auburn University, Auburn, AL, ³University of Alabama at Birmingham, Hoover, AL, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Global Healthy Living Foundation, Upper Nyack, NY, ⁶Berkshire Medical Center, Lenox, MA
Background/Purpose: We aimed to assess enthusiasm for the use of virtual reality (VR) for clinical and educational use among people with rheumatologic diseases, comparing those…
Abstract Number: 0249 • ACR Convergence 2022
Identification of Distinct Peripheral Blood Myeloid Cell Subpopulations in Patients with Rheumatoid Arthritis-associated Interstitial Lung Disease
Jill Poole¹, Bryant England¹, Kathryn Cole¹, James Talmadge¹, Amy Nelson¹, Rohit Gaurav¹, Aaron Schwabb¹, Angela Gleason¹, Michael Duryee¹, Rhonda Walenz¹, Bridget Kramer¹, Joel VanDeGraaff¹, Sara May¹, Geoffrey Thiele¹ and Ted Mikuls², ¹University of Nebraska Medical Center, Omaha, NE, ²Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Interstitial lung disease (ILD) is associated with significant morbidity and mortality in rheumatoid arthritis (RA). The key cellular players of RA-ILD remain largely unknown.…
Abstract Number: 0265 • ACR Convergence 2022
In Patients with Rheumatoid Arthritis, Clinical Examination of the Feet Is Important for Understanding Individual Disease Burden, but Does Not Provoke a Change in Therapy in Most Cases
Nicolai Leuchten, Christoph Weinert and Martin Aringer, University Medical Center and Faculty of Medicine TU Dresden, Dresden, Germany
Background/Purpose: Disease activity scores like CDAI, SDAI, or DAS28, are essential for measuring rheumatoid arthritis (RA) disease activity. These scores do not contain foot joints.…
Abstract Number: 0283 • ACR Convergence 2022
The Association Between the Usage of Biological Disease Modified Anti Rheumatic Drug or JAK Inhibitor and the Burden of Treatment Costs on Daily Life (financial Toxicity) in RA Patients: A Cross-sectional Study Using the National Database of Rheumatic Diseases in Japan (NinJa)
Nobuyuki Yajima¹, Toshihiro Matsui² and Shigeto Tohma³, ¹Division of Rheumatology, Department of Medicine, Showa University School of Medicine, Tokyo, Japan, ²NHO Sagamihara National Hospital, Kanagawa, Japan, ³National Hospital Organization Tokyo National Hospital, Dallas, TX
Background/Purpose: Rheumatoid arthritis (RA) can be better controlled with the advent of biological disease modified anti rheumatic drug (bDMARDs) and JAK inhibitor (JAKi). However, these…
Abstract Number: 0299 • ACR Convergence 2022
Radiographic Change in Patients with Rheumatoid Arthritis and Estimated Baseline Yearly Progression ≥5 or < 5: Post Hoc Analysis of Two Phase 3 Trials of Filgotinib
Yoshiya Tanaka¹, Tatsuya Atsumi², Daniel Aletaha³, Robert Landewé⁴, Beatrix Bartok⁵, Alena Pechonkina⁶, Ling Han⁶, Kahaku Emoto⁷, Shungo Kano⁷, Vijay Rajendran⁸ and Tsutomu Takeuchi⁹, ¹University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ²Hokkaido University, Sapporo, Japan, ³Medical University Vienna, Wien, Austria, ⁴Amsterdam University Medical Center, Meerssen, Netherlands, ⁵Gilead Sciences, Inc., La Jolla, CA, ⁶Gilead Sciences, Foster City, CA, ⁷Gilead Sciences, K.K., Tokyo, Japan, ⁸Galapagos NV, Gent, Belgium, ⁹Keio University and Saitama Medical University, Tokyo, Japan
Background/Purpose: In some patients (pts) with rheumatoid arthritis (RA), especially those with joint damage early in the disease, first-line methotrexate (MTX) treatment may not suffice…
Abstract Number: 0398 • ACR Convergence 2022
Comparison of Spondyloarthritis, Rheumatoid Arthritis and Knee Osteoarthritis Occurring in the Setting of HIV Infection
Benjamin Naovarat¹, John Reveille¹, Mark Hwang², Francis Williams³ and Gloria Salazar⁴, ¹University of Texas McGovern Medical School, Houston, TX, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³Specialists for Health/Wellmed, Shavano Park, TX, ⁴University of Texas Medical School at Houston/McGovern Medical School, Houston, TX
Background/Purpose: Early in the HIV epidemic, autoimmune diseases such as lupus and rheumatoid arthritis (RA) were uncommonly encountered. With the advent of combined antiretroviral therapy…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].